Lanreotide Injection 120 mg/0.5 mL
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL due to a lack of assurance of sterility.
Contact your healthcare provider if you have concerns about your medication. Do not use the product if you have questions regarding its sterility.
Why it was recalled
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
How to identify it
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only, Rx Only, Manufactured by: Pharmathen International, S.A., Rodopi, Greece. Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC 69097-906-67
Where it was sold
Distributed in US.
Official source
Other recent recalls from Cipla USA, Inc.
Editorial summary by Recall Canary · last updated 2026-06-05 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification